New asthma inhaler study for mild to moderate asthma
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether a new inhaler (CHF5993) works as well as the current standard for adults with mild to moderate asthma. It compares how well the medicine controls asthma and opens airways.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You do not smoke or quit smoking more than a year ago.
- Your asthma is stable on a low or medium dose of inhaled steroid (with or without a long-acting bronchodilator).
- You have not needed oral steroids or an ER visit for asthma in the last 3 months.
- Your lung function (FEV1) is between 40% and 90% of normal, and it increases by at least 12% after using albuterol.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new three-part asthma inhaler (CHF 5993) in people whose asthma isn't well-controlled even though they're already using two standard asthma medicines together. The goal is to see if adding this new medicine helps control asthma better.
This trial tests whether a new combination inhaler works as well as a commonly used one for teenagers with asthma that is not well controlled. It aims to find a safe and effective treatment option for adolescents.
This study compares two versions of the common asthma rescue inhaler (salbutamol/albuterol) that use different propellants (the gas that pushes the medicine out). The goal is to see if the new propellant works as well as the current one. If you have mild asthma and are on a stable treatment plan, you may be able to join.
This study tests a new inhaler (PT027) against another inhaler (PT007) for teens aged 12 to 17 with asthma. It looks at how well the new inhaler works when used as needed, and if it is safe.
This trial tests a new combination inhaler (QVM149) against a standard one (Advair) in teenagers with asthma that isn't well controlled by their current medicine. It aims to see if the new inhaler works better.
This early-phase study tests an inhaled medication (CHF10136) to see if it's safe and how the body handles it. It includes both healthy adults and people with asthma, and participants will be monitored closely throughout.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.